title: Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonists.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
authors.forename: Clément
authors.initials: C
authors.lastname: Prati
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D018664:Interleukin-12 / Q000037:antagonists & inhibitors / Q000502:physiology; D020381:Interleukin-17 / Q000037:antagonists & inhibitors / Q000502:physiology; D015850:Interleukin-6 / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000069549:Ustekinumab; D000093242:Interleukin-6 Inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D018664:Interleukin-12; D020381:Interleukin-17; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D000069549:Ustekinumab; D000093242:Interleukin-6 Inhibitors; C555450:secukinumab; C502936:tocilizumab